Andrew J. Muir, MD, MHS
Hepatologist, Transplant Hepatologist
My Locations
About Me
I am proud to serve as the Chief of the Duke Division of Gastroenterology. In addition to my administrative duties, I enjoy my clinical practice focused on the care of patients with liver diseases. I also continue to participate in clinical research and hope that these studies offer our patients the latest advances and treatment options.
- Professor of Medicine, Medicine, Gastroenterology 2016
- Chief, Division of Gastroenterology in the Department of Medicine, Medicine, Gastroenterology 2014
- Core Faculty in Innovation & Entrepreneurship, Duke Innovation & Entrepreneurship 2021
Call for an Appointment
Ratings and Reviews
The ratings and reviews are based on patient responses to the overall provider rating question from the survey. The question reads: “Using any number from 0 to 10, where 0 is the worst provider possible and 10 is the best provider possible, what number would you use to rate this provider?” Responses are converted to a 5-point rating system and applied consistently to all providers. Learn more about our survey process. Patients who see some types of providers receive a different version of the patient satisfaction survey. Those results are not available on DukeHealth.org.
Training and Education
In the News
Loading
Clinical Focus and Research
We take part in studies of new therapies for patients with liver disease. Through our clinical trials, we can offer patients other treatment options and often earlier access to new therapies. It has been my privilege to take part in many of the studies of new drugs for hepatitis C over the last decade. These treatments are now available in our clinical practice, and we are very comfortable with these new drugs, given our experience in these clinical trials over the last several years. With the progress in hepatitis C, we are now turning our attention to other liver diseases. I have personally started to focus on primary sclerosing cholangitis and cirrhosis.
- Endocrinology and Metabolism Training Program awarded by National Institutes of Health 2024 - 2029
- The Southeastern Liver Health Cohort Study awarded by North Carolina State University 2023 - 2027
- Muir, Andrew J., Fred F. Poordad, John G. McHutchison, Mitchell L. Shiffman, Thomas Berg, Peter Ferenci, E Jenny Heathcote, et al. “Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.” Hepatology 54, no. 5 (November 2011): 1538–46. https://doi.org/10.1002/hep.24549.
- Muir, Andrew J. “The protease inhibitor era: an opportunity to improve the quality of care.” Dig Dis Sci 56, no. 5 (May 2011): 1252–54. https://doi.org/10.1007/s10620-011-1674-2.
- Muir, A. J., K. -. Q. Hu, S. C. Gordon, K. Koury, N. Boparai, S. Noviello, J. K. Albrecht, M. S. Sulkowski, and J. McCone. “Hepatitis C treatment among racial and ethnic groups in the IDEAL trial.” J Viral Hepat 18, no. 4 (April 2011): e134–43. https://doi.org/10.1111/j.1365-2893.2010.01402.x.
- Muir, A. J. “Treatment of Hepatitis C.” In Zakim and Boyer’s Hepatology: A Textbook of Liver Disease, 446–63, 2017. https://doi.org/10.1016/B978-0-323-37591-7.00030-6.
- Jazwinski, A. B., and A. J. Muir. “The genetics of virologic response.” In Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future, 183–92, 2012. https://doi.org/10.1007/978-1-4614-1192-5_15.
- Sanyal, Arun J., Quentin M. Anstee, Michael Trauner, Eric J. Lawitz, Manal F. Abdelmalek, Dora Ding, Ling Han, et al. “Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.” In Hepatology, 75:1235–46, 2022. https://doi.org/10.1002/hep.32204.
- Kappus, Matthew R., Kara Wegermann, Erol Bozdogan, Yuval A. Patel, Gemini Janas, Erin Shropshire, Alice Parish, Donna Niedzwiecki, Andrew J. Muir, and Mustafa Bashir. “Use of Skeletal Muscle Index as a Predictor of Wait-List Mortality in Patients With End-Stage Liver Disease.” In Liver Transpl, 26:1090–99, 2020. https://doi.org/10.1002/lt.25802.
- Wegermann, Kara, Julius Wilder, Alice Parish, Donna Niedzwiecki, Ziad F. Gellad, Andrew Joseph Muir, and Yuval Patel. “BLACK, OLDER, UNMARRIED, AND MEDICAID PATIENTS WERE LESS LIKELY TO COMPLETE HEPATOLOGY VIDEO VISITS DURING COVID-19.” In HEPATOLOGY, 72:382A-383A, 2020.
Insurance Accepted
Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below.
-
Aetna
- Aetna Choice POS, Aetna Choice POS II
- Aetna Elect Choice HMO, Aetna Open Access Elect Choice
- Aetna Health Network Only, Aetna Health Network Option
- Aetna HMO
- Aetna Limited Benefit Insurance PPO
- Aetna Managed Choice POS
- Aetna Medicare Assure Plan (HMO D-SNP)
- Aetna Medicare Eagle Plan (PPO)
- Aetna Medicare Essential Plan (PPO)
- Aetna Medicare Value Plan (HMO)
- Aetna Open Access HMO, Open Access Aetna Select, Aetna Open Access Managed Choice
- Aetna Open Choice PPO
- Aetna PCP Coordinated POS Plan
- Aetna Quality Point of Service (QPOS)
- Aetna Select HMO
- Aetna Traditional Choice
- Aetna Voluntary Indemnity Group Plan
- Aetna Whole Health – Duke WakeMed WKCC
- Aetna/CVS Health
-
Ambetter
- Ambetter of North Carolina
-
Blue Cross Blue Shield of NC
- Blue Advantage
- Blue Medicare (HMO, PPO)*
- Blue Options (123, PPO, HSA)
- Blue Select
- NC State Employees Health Plan
-
*Duke HomeCare and Hospice does not participate in the plan.
-
Cigna
- Cigna Behavioral Health (*Limited eligibility)
- Cigna Choice Plus
- Cigna Connect Individual Family Plan
- Cigna Open Access
- Cigna Open Access Plus
-
*Please call Cigna Behavioral Heath to see if the provider is participating in your plan.
-
Duke Group Plans
- Duke Basic
- Duke Select
-
Experience Health
- Experience Health Medicare Advantage (HMO) Plan
- Gateway Health Alliance
- Healthgram
-
Humana
- Humana Choice (PPO)
- Humana Choice - Medicare Advantage (PPO)
- Humana ChoiceCare - Medicare Advantage (PPO)
- Humana Gold Choice - Medicare Advantage (PFFS)
- Humana Gold Plus - Medicare Advantage (HMO)
- Humana Medicare Advantage Group Plan - NC State Retirees
- MedCost
-
Medicare
- First Medicare Direct
- Medicare Part A
- Medicare Part B
-
NC Medicaid
- AmeriHealth Caritas North Carolina
- Carolina Complete Health
- Healthy Blue
- NC Medicaid Direct
- WellCare of North Carolina
-
TRICARE
- TRICARE Prime
- TRICARE Prime Remote
- TRICARE Select
-
United Healthcare
- AARP Medicare Advantage Plan 2 (HMO-POS)
- AARP Medicare Complete (HMO, PPO)*
- AARP Medicare Complete Essential (HMO)*
- All Savers Alternate Funding
- All Savers Fully Insured
- United Healthcare (HMO, PPO, POS)**
- United Healthcare Charter/Charter Balance/Charter Plus
- United Healthcare Choice/Choice Plus
- United Healthcare Core/Core Essential
- United Healthcare Navigate/Navigate Plus/Navigate Balanced
- United Healthcare Option PPO
- United Healthcare Passport Connect Choice/Choice Plus
- United Healthcare Passport Connect Options PPO
- United Healthcare Select/Select Plus
- United Healthcare Shared Services - Harvard Pilgrim/UHC Options PPO Network
- United Medical Resources (UMR)
-
*Duke HomeCare and Hospice and mental health providers do not participate with the plan.
-
**Duke Health does not participate in UHC plans on the Health Insurance Marketplace.
Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.
External Relationships
- Cour Pharmaceuticals
- Cymabay
- Gilead Sciences, Inc.
- Mirum Pharmaceuticals
- NGM Biopharmaceuticals
- Ultragenyx